NASDAQ NMS - GLOBAL MARKET · TYRA
+5.32% · +$1.30 · Vol 2.1M
Market closed · last close 4:00 PM ET · price as of 16:21:28 ET
Tyra Biosciences Inc

Tyra Biosciences Inc

Biotechnology
$25.73
Card
Relationship Map

Follow $TYRA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $TYRA by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
TYRA
Tyra Biosciences Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 5 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is TYRA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading TYRA catalysts
About Tyra Biosciences Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
87
Country
US

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$24.58
Day high
$25.88
Day low
$24.40
Previous close
$24.43
52W high
$39.61
-35.04% from high
52W low
$12.50
49% of range
Market cap
$1.8B
EPS
$-2.3000
Beta
0.47
Shares out
68.8M
Volume
2.1M
2.15× rel vol
Avg volume
964.7K
VWAP
$25.54
Price history computed in-house
1W
+16.80%
1M
+0.16%
3M
-9.15%
1Y
+105.84%
YTD
-2.13%
SMA 50 $27.75 · below
SMA 200 $30.49 · below
52W position 49%

TYRA overview

Loading financial statements
Loading TYRA Form 4 filings
Public disclosures

Congress activity in TYRA

No receipt-qualified Congressional disclosure is present for TYRA in the cached public ledger.

Federal contracts

TYRA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TYRA in this window.
Lobbying spend

TYRA lobbying filings, year to date.

Registered lobbying filings matched to Tyra Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TYRA in this window.
Loading news for TYRA
Analyst ratings
Sovereign unlock shows live analyst consensus for TYRA.
Options
Sovereign unlock shows live options positioning for TYRA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.